Compare KMT & KARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KMT | KARD |
|---|---|---|
| Founded | 1938 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.9B |
| IPO Year | 1994 | 2026 |
| Metric | KMT | KARD |
|---|---|---|
| Price | $29.72 | $20.10 |
| Analyst Decision | Hold | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $36.00 | N/A |
| AVG Volume (30 Days) | ★ 1.7M | 215.1K |
| Earning Date | 05-06-2026 | N/A |
| Dividend Yield | ★ 2.08% | N/A |
| EPS Growth | ★ 268.33 | N/A |
| EPS | ★ 4.42 | N/A |
| Revenue | ★ $2,356,698,000.00 | N/A |
| Revenue This Year | $14.24 | N/A |
| Revenue Next Year | $7.57 | N/A |
| P/E Ratio | $6.83 | ★ N/A |
| Revenue Growth | ★ 19.82 | N/A |
| 52 Week Low | $20.35 | $19.58 |
| 52 Week High | $43.81 | $27.00 |
| Indicator | KMT | KARD |
|---|---|---|
| Relative Strength Index (RSI) | 39.57 | 45.82 |
| Support Level | $28.23 | $19.67 |
| Resistance Level | $35.50 | $23.02 |
| Average True Range (ATR) | 0.99 | 1.40 |
| MACD | -0.03 | 0.03 |
| Stochastic Oscillator | 36.20 | 23.97 |
Kennametal Inc is a manufacturer of metalworking tools and wear-resistant engineered components and coatings. The company operates in two business segments; Metal Cutting and Infrastructure. It generates maximum revenue from the Metal Cutting segment. The Metal Cutting segment develops and manufactures high-performance tooling and metal cutting products and services and offers an assortment of standard and custom metal cutting solutions to diverse end markets, including aerospace, general engineering, energy, and transportation. Geographically, it derives maximum revenue from the United States and the rest from Germany, China, Canada, India, Italy, and other countries.
Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.